Summary & Overview
HCPCS J1630: Haloperidol Injection, Up to 5 mg
HCPCS Level II code J1630 denotes the administration of haloperidol injection, up to 5 mg. This code is used to bill for a single parenteral dose of haloperidol, an antipsychotic commonly used for acute agitation, psychosis, and behavioral disturbances. Nationally, accurate coding for injectable psychotropic medications affects clinical workflow, inpatient and emergency department throughput, and medication cost accounting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J1630, payer coverage considerations, and typical sites of service. The publication summarizes billing benchmarks where available, common modifier usage, and relevant policy or reimbursement updates impacting injectable antipsychotic billing practice.
The guide is intended for coding staff, revenue cycle managers, and clinical leaders who need clarity on when to apply J1630, how it fits into service lines that manage acute psychiatric presentations, and what documentation and billing considerations commonly arise in both inpatient and outpatient settings. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1630 represents an injection of haloperidol, up to 5 mg. This code describes a single administration of haloperidol for therapeutic use, typically delivered by intramuscular or intravenous injection depending on clinical setting and formulation. The service type is an injectable antipsychotic medication administration, and the typical site of service includes inpatient hospital wards, emergency departments, psychiatric emergency services, and outpatient clinics or ambulatory care settings where parenteral antipsychotic therapy is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or outpatient behavioral health clinic with acute agitation or psychosis due to schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, or severe delirium. The attending psychiatrist or emergency physician assesses the patient, documents mental status, attempts verbal de-escalation, and determines that intramuscular antipsychotic injection is required for immediate control of dangerous or noncooperative behavior. The clinician orders J1630 for haloperidol up to 5 mg administered intramuscularly. Nursing documents informed consent when possible, verifies allergies, prepares medication per facility protocol, selects appropriate injection site (typically deltoid or ventrogluteal), performs injection, monitors vital signs and level of sedation, and documents medication administration, dose, time, route, lot number, and patient response. Observation continues until the patient is clinically stable or transferred to an inpatient psychiatric unit. Billing uses J1630 to report the drug supply and may append an appropriate modifier for payer, laterality, or service circumstance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-dose vial is discarded and payer requires reporting of wasted biologic/drug. |